Knight Therapeutics Inc. has seen a steady climb in its stock performance recently amid significant company announcements.
This week, Knight Therapeutics Inc. (GUD.TO) experienced a modest increase in its stock price, closing at C$10.71, reflecting a 1.74% gain for the day and a 1.84% increase over the past week. The company has been making headlines with recent regulatory and partnership developments that may be influencing investor sentiment.
Advertisement
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeMarket cap
$1.04B
P/E
70.3x
52W high
$10.80
52W low
$5.66
1W change
+1.84%
Beta
-0.01
Analyst Price Targets
Based on analyst covering GUD · as of Sep 17, 2026
Wall Street analysts forecast GUD stock price to rise 6.1% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$11.19
+6.1% Upside
Current Price
C$10.54
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
23.4%
Annualized
90-Day Vol
26.9%
Annualized
Trend (90d)
+30.6%
Annualized drift
90d Mean
C$11.76
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$10.93 | C$10.08 – C$11.85 |
| 60 trading days | C$11.34 | C$10.11 – C$12.70 |
| 90 trading days | C$11.76 | C$10.22 – C$13.52 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Knight Therapeutics continues to expand its portfolio and market presence through strategic partnerships and regulatory approvals, which could bolster its long-term growth prospects.
Stock Performance and Volume Insights
Knight Therapeutics has seen a strong year-to-date performance with a 78.34% increase, although its recent trading volume is slightly below its 20-day average.
Bull case
The recent regulatory approval of NIKTIMVO® in Brazil and exclusive distribution agreements for POTELIGEO® position Knight Therapeutics well in the growing oncology market in Latin America. These moves could significantly enhance the company's market presence and revenue potential in this sector.
Bear case
Despite recent gains, the company's high P/E ratio of 70.27 and low profit margin of 2.7% raise concerns about its valuation and profitability moving forward. Investors may want to consider these factors before making decisions.
Recent Company News
Knight Therapeutics has made significant strides recently with several key announcements. On October 6, the company announced the regulatory approval of NIKTIMVO® in Brazil, which could enhance its market presence in the country. Additionally, on September 29, Knight entered into exclusive distribution agreements with Kyowa Kirin for POTELIGEO® (mogamulizumab), aimed at treating Cutaneous T-Cell Lymphoma (CTCL) patients across Latin America. These developments may indicate a strategic focus on expanding its oncology product offerings.
Advertisement
Technical Picture
Knight Therapeutics is currently trading at C$10.71, which is above both its 50-day moving average of C$9.85 and its 200-day moving average of C$8.06, indicating a bullish trend. The stock has a 52-week range of C$5.66 to C$10.80, with its current price sitting at 98% of this range. The beta of -0.01 suggests low volatility compared to the market, while its trading volume of 61,289 shares is slightly below the 20-day average of 72,164 shares, indicating a potential decrease in trading activity.
Fundamental Overview
From a fundamental perspective, Knight Therapeutics has a market capitalization of approximately C$1.04 billion. It has a price-to-earnings (P/E) ratio of 70.27, which is relatively high, indicating potential overvaluation. The company's profit margin stands at 2.7%, and its return on equity (ROE) is 1.9%, suggesting that while the company is growing, its profitability metrics may raise concerns among investors looking for value.
Analyst Outlook
Analysts have set an average target price of C$11.19 for Knight Therapeutics, implying a potential upside of about 4.4% from the last closing price. The overall outlook remains neutral, suggesting that while there is room for growth, investors should remain cautious given the high valuation metrics.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
